1. The lauric acid-activated signaling prompts apoptosis in cancer cells
    Rosamaria Lappano et al, 2017, Cell Death Discovery CrossRef
  2. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
    Chiara Zagni et al, 2017, Med. Res. Rev. CrossRef
  3. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine
    Xia Li et al, 2017, Biomedicine & Pharmacotherapy CrossRef
  4. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells
    Sheng Yang et al, 2018, Biomedicine & Pharmacotherapy CrossRef
  5. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway
    Jianan Zhou et al, 2018, Invest New Drugs CrossRef
  6. Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
    Ruolan Gu et al, 0 CrossRef
  7. Cerebrospinal fluid from rats given hypoxic preconditioning protects neurons from oxygen-glucose deprivation-induced injury
    Yan-bo Zhang et al, 2015, Neural Regen Res CrossRef
  8. PXD101 analogs withL-phenylglycine-containing branched cap as histone deacetylase inhibitors
    Jingyao Li et al, 2016, Chem Biol Drug Des CrossRef
  9. Indole: A privileged scaffold for the design of anti-cancer agents
    Yichao Wan et al, 2019, European Journal of Medicinal Chemistry CrossRef
  10. Increased sensitivity of African American triple negative breast cancer cells to nitric oxide-induced mitochondria-mediated apoptosis
    Luis Martinez et al, 2016, BMC Cancer CrossRef
  11. Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 Degradation.
    Mu He et al, 0 CrossRef
  12. Development of N -hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity
    Jie Zang et al, 2017, Bioorganic & Medicinal Chemistry CrossRef
  13. Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially forp16-deleted patients through DNA damage
    Pengcheng Shi et al, 2017, Pharmacogenomics CrossRef
  14. The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer

    Wanjun Zhang et al, 2020, OTT CrossRef
  15. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy
    Yue Xie et al, 2020, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy CrossRef
  16. Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR‑33a‑5p‑LDHA axis
    Xiangdong Bai et al, 2019, Mol Med Report CrossRef
  17. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase‑dependent manner
    Xiang‑Gui Yuan et al, 2019, Oncol Lett CrossRef
  18. Chidamide acts on the histone deacetylase‐mediated miR ‐34a/Bcl‐2 axis to regulate NB4 cell line proliferation and apoptosis
    Jie Peng et al, 2020, The Kaohsiung Journal of Medical Sciences CrossRef
  19. HDAC–Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells
    Tao Liang et al, 2020, J. Med. Chem. CrossRef
  20. Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway.
    Liman Lin et al, 2020, Front Pharmacol CrossRef
  21. HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target.
    Lulu Liu et al, 2021, J Mol Med (Berl) CrossRef
  22. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway
    Hao Wang et al, 2020, J Exp Clin Cancer Res CrossRef
  23. Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: An unusual case report and literature review
    Liangliang Li et al, 2021, Int J Immunopathol Pharmacol CrossRef
  24. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
    Reid P. Bissonnette et al, 2021, BMC Cancer CrossRef
  25. Anticancer activity of N-heteroaryl acetic acid salts against breast cancer; in silico and in vitro investigation
    Samaneh Zolghadri et al, 2021, Mol Biol Rep CrossRef
  26. New Multi-Targeted Antiproliferative Agents: Design and Synthesis of IC261-Based Oxindoles as Potential Tubulin, CK1 and EGFR Inhibitors
    Momen R. Fareed et al, 2021, Pharmaceuticals CrossRef
  27. Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model
    Shao-Chuan Wang et al, 2022, Cancer Letters CrossRef
  28. Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
    Yichen Sun et al, 2022, Front. Pharmacol. CrossRef